also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Michael Prince/McKesson




America’s largest drug distributor is under new leadership after its long-serving CEO—and consistently one of the country’s highest paid—John Hammergren retired in April. He left the wholesaler much expanded from when he began his run at the company 17 years ago. That trend continued in 2018: Revenue grew 4.9% due to rising drug prices, increased sales to existing customers, and through acquisitions. Profits took a hit partly because of one-time charges involving its European business and Rexall, a Canadian drug store chain McKesson acquired in 2016. Like its two major competitors, McKesson is facing a growing number of lawsuits for its alleged role in the nation’s opioid epidemic; it has denied any wrongdoing.

Looking for leads, investment insights, or competitive intelligence?


Brian S. Tyler

CEO Title

President, Chief Executive Officer & Director


Health Care


Wholesalers: Health Care

HQ Location

Irving, Texas

Years on Fortune 500 List




Figures are for fiscal year ended March 31, 2018.
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$208,3574.9%
Profits ($M)$67.0-98.7%
Assets ($M)$60,381
Total Stockholder Equity ($M)$9,804
Profit Ratios
Profit as % of Revenues0.0%
Profits as % of Assets0.1%
Profits as % of Stockholder Equity0.7%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)0.32
EPS % Change (from 2017)-98.6%
EPS % Change (5 year annual rate)-43.6%
EPS % Change (10 year annual rate)-20.9%
Total Return
Total Return to Investors (2018)-28.4%
Total Return to Investors (5 year, annualized)-6.7%
Total Return to Investors (10 year, annualized)12.0%
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about McKesson

6 More States Just Sued the Oxycontin Maker. How It Could Dramatically Alter the Price of an Opioid Settlement

The decision to sue is seen as an acknowledgment opioid makers won’t get serious about settling until the cases go to trial.

Read More →
Why Trump's Big Drug Price Speech Sent Health Care Stocks Soaring

The president's drug price proposals didn't shake big pharma and other health care companies.

Read More →
The Justice Department Is Getting In on the War on Opioids

Attorney General Jeff Sessions announced a "statement of intent" to prop up suits against opioid makers and distributors.

Read More →
Amazon, Berkshire Hathaway and J.P. Morgan Are Forming a Non-Profit Health Care Venture

Sparking a selloff in the shares of a host of health care-related companies.

Read More →